Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 31 to 40 of 2440 total matches.
Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines (online only)
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
0, 2nd at week 3, and 3rd ?8 weeks after dose 2
1 previous Pfizer dose: 1 3-mcg dose ?3 weeks later ...
View the Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e1 doi:10.58347/tml.2023.1687e | Show Introduction Hide Introduction
Clindamycin-Tretinoin (Veltin Gel) for Acne
The Medical Letter on Drugs and Therapeutics • Dec 13, 2010 (Issue 1353)
combination of the
antibiotic clindamycin phosphate 1.2% and the retinoid
tretinoin 0.025 ...
Veltin Gel (Stiefel), a fixed-dose combination of the
antibiotic clindamycin phosphate 1.2% and the retinoid
tretinoin 0.025%, has been approved by the FDA for topical
treatment of acne vulgaris in patients ≥12 years old.
Another product containing the same active ingredients
(Ziana) has been on the market since 2006.
Ertugliflozin for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018 (Issue 1545)
as monotherapy or in
addition to other drugs, they reduce A1C by 0.5-1%.
SGLT2 inhibitors also reduce systolic ...
The FDA has approved the sodium-glucose co-transporter
2 (SGLT2) inhibitor ertugliflozin (Merck)
for treatment of adults with type 2 diabetes, both
alone (Steglatro) and in fixed-dose combinations
with metformin (Segluromet) and sitagliptin
(Steglujan). Ertugliflozin is the fourth SGLT2 inhibitor
to be approved in the US. All four are available in
combination with metformin and three are available
in combination with a dipeptidyl peptidase-4 (DPP-4)
inhibitor (see Table 3).
Brinzolamide/Brimonidine (Simbrinza) for Glaucoma
The Medical Letter on Drugs and Therapeutics • Jul 22, 2013 (Issue 1421)
such as hyperemia, burning,
foreign body sensation and allergy may be difficult
to tolerate. A 0.1% and 0.15 ...
The FDA has approved Simbrinza (Alcon), an ophthalmic
combination of the carbonic anhydrase inhibitor
brinzolamide and the selective alpha2-adrenergic
receptor agonist brimonidine, for reduction of intraocular
pressure (IOP) in patients with open-angle glaucoma or
ocular hypertension. Simbrinza is the first product to
combine drugs from these 2 classes.
Lenacapavir (Sunlenca) for Multidrug-Resistant HIV
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
formulations of the HIV-1 capsid inhibitor lenacapavir
(Sunlenca – Gilead) for use with other antiretroviral ...
The FDA has approved oral and injectable
formulations of the HIV-1 capsid inhibitor lenacapavir
(Sunlenca – Gilead) for use with other antiretroviral
drugs to treat multidrug-resistant HIV-1 infection
(MDR-HIV) in heavily treatment-experienced adults
whose current regimen is failing. Lenacapavir is the
third drug to be approved exclusively for treatment
of MDR-HIV; the intravenously administered CD4-directed antibody ibalizumab-uiyk (Trogarzo) and the
orally administered HIV-1 gp120-directed attachment
inhibitor fostemsavir (Rukobia) were approved earlier.
Med Lett Drugs Ther. 2023 May 1;65(1675):68-70 doi:10.58347/tml.2023.1675c | Show Introduction Hide Introduction
Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines (online only)
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
Not Previously Vaccinated
Previously Vaccinated with Monovalent Vaccine2
Previously Received ?1 Bivalent Dose3 ...
View the Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines
Med Lett Drugs Ther. 2023 May 1;65(1675):e1 doi:10.58347/tml.2023.1675f | Show Introduction Hide Introduction
Insulin Degludec (Tresiba) - A New Long-Acting Insulin for Diabetes
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015 (Issue 1483)
) for treatment of adults with type 1 or
type 2 diabetes. Insulin degludec is the third longacting
human insulin ...
The FDA has approved insulin degludec (Tresiba –
Novo Nordisk) for treatment of adults with type 1 or
type 2 diabetes. Insulin degludec is the third long-acting
human insulin analog to be approved by the
FDA; insulin detemir (Levemir) and insulin glargine
(Lantus, Toujeo) were approved earlier.
Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015 (Issue 1463)
-chain that increases its activity against
Pseudomonas aeruginosa.1 Tazobactam inhibits most
class ...
The FDA has approved ceftolozane/tazobactam
(Zerbaxa – Cubist), a combination of a new cephalosporin
antibiotic and a beta-lactamase inhibitor, for
intravenous treatment of complicated urinary tract
and intra-abdominal infections in adults.
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022 (Issue 1643)
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
The FDA has approved Vuity (Abbvie), a 1 ...
The FDA has approved Vuity (Abbvie), a 1.25%
ophthalmic solution of the muscarinic receptor
agonist pilocarpine hydrochloride, for treatment of
presbyopia in adults. Pilocarpine 1%, 2%, and 4%
ophthalmic solutions (Isopto Carpine, and others)
have been available for years for treatment of
glaucoma, but local and systemic adverse effects
have limited their use.
Clascoterone Cream (Winlevi) for Acne
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021 (Issue 1640)
not respond to topical combination therapy, addition
of an oral tetracycline is recommended.1,2 The most ...
The FDA has approved Winlevi (Sun), a 1% cream
formulation of the androgen receptor inhibitor
clascoterone, for treatment of acne vulgaris in
patients ≥12 years old. It is the first topical androgen
receptor inhibitor to be approved by the FDA.